Colorado joined the federal government and 38 other states and territories to settle with Pfizer over alleged migraine drug ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, ...

Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec.

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine ...

Attorney General Mike Hilgers announced Tuesday, Nebraska has joined the United States, 37 other states, and Puerto Rico to ...

A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...